Matthew Lee Bloom, DO
Physical Medicine and Rehabilitation · Ventura
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 12 years
- College of Osteo Med of the Pacific at Pomona, 2014
Offices
2 locations
Hospitals listed: St Johns Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bloom’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- St Johns Regional Medical CenterOxnard, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.06 (90.32 to 169.81) · 120 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.404, Oct 2024 – Sep 2025
See every measure and the patient survey for St Johns Regional Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.06 (90.32 to 169.81) · 120 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.404 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.8 (0 to 1.75) · 1,494 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.56 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 159 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 8.7 · 279 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.1 · 580 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.6 · 654 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,404 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 8,124 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.39) · 8,331 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.92 (1.89 to 5.95) · 1,414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.17 (0.6 to 3.75) · 412 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.94 (0.46 to 3.43) · 1,361 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.75 (0.73 to 12.78) · 439 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.94 (3.39 to 10.49) · 383 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.94 (0.47 to 3.41) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.11 (0 to 0.67) · 7,172 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 88 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.236 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.331 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.571 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.737 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 336 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 715 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -8.1 · 284 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.6 · 648 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -9.1 · 674 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.9 · 670 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (5.2 to 8.9) · 428 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (8.6 to 13.5) · 428 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 98 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 196 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.5 to 18.8) · 247 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 486 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,151 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$540,680
Medicare paid this office $540,680 for 753 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Botox | 41 | $183,537 | None |
| Telephone medical discussion with physician, 21-30 minutes | 314 | $102,461 | $99 |
| Return visit (30+ min) | 342 | $89,745 | $86 |
| Muscle electrical test | 188 | $23,998 | $76 |
| New patient visit (45+ min) | 152 | $18,276 | $120 |
See all 33 services
| Botox | 41 | $183,537 | None |
| Telephone medical discussion with physician, 21-30 minutes | 314 | $102,461 | $99 |
| Return visit (30+ min) | 342 | $89,745 | $86 |
| Muscle electrical test | 188 | $23,998 | $76 |
| New patient visit (45+ min) | 152 | $18,276 | $120 |
| Nerve test | 108 | $17,542 | $151 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 83 | $12,151 | $86 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 65 | $8,722 | $105 |
| Nerve test | 81 | $8,273 | $97 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 27 | $6,119 | $211 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $5,651 | $58 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 16 | $5,647 | $123 |
| Muscle electrical test | 23 | $4,448 | $60 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 27 | $4,367 | $99 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 15 | $4,272 | $112 |
| Injection of trigger points, 3 or more muscles | 50 | $4,097 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $3,214 | $87 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 13 | $2,863 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $2,543 | $127 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 25 | $2,225 | $54 |
| Ultrasonic guidance for needle placement | 29 | $1,832 | $46 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 25 | $1,705 | $63 |
| Injection of carpal tunnel | 16 | $1,675 | $80 |
| Injection of substance into lower spine canal using imaging guidance | 20 | $1,632 | $74 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 16 | $1,522 | $80 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 29 | $1,416 | $39 |
| Injection of substance into middle or upper spine canal using imaging guidance | 16 | $1,281 | $80 |
| Hospital discharge day management, 30 minutes or less | 20 | $1,204 | $60 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $1,197 | $70 |
| Short return visit (20+ min) | 13 | $846 | $56 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 17 | $191 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 69 | $92 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $2 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 45 | 89 | 83 | 76 | 102 | 141 |
| Injection of trigger points, 3 or more muscles | – | 72 | 140 | 96 | 118 | 95 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | – | – | – | 37 | 45 | 46 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | – | – | – | 40 | 44 | 38 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | – | – | – | – | – | 83 |
| Injection of trigger points, 1-2 muscles | – | 43 | 22 | 11 | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
753 Original Medicare patients in 2024. Average age 71 · Under 65 20% · 85 and older 10% · Women 59% · Also on Medicaid 51% · Health risk score 1.62. Above the middle of the specialty; the typical physical medicine and rehabilitation clinician is at 1.53.
Conditions among them: High blood pressure 75% · Diabetes 40% · Depression 34% · Coronary heart disease 27% · Chronic kidney disease 24% · COPD 17% · Atrial fibrillation 17% · Heart failure 16% · Stroke 15% · Cancer 9% · Dementia 8%.
The office billed $4,881,617, Medicare allowed $717,247 and paid $540,680; for 41,246 services of 63 kinds; $190,026 of it was for drugs given in the office and $350,654 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 753 | 41,246 | 71 | 1.62 | $4,881,617 | $540,680 |
| 2023 | 594 | 39,384 | 70 | 1.65 | $1,348,235 | $490,791 |
| 2022 | 585 | 35,924 | 71 | 1.72 | $1,034,767 | $430,903 |
| 2021 | 455 | 22,662 | 71 | 1.75 | $742,816 | $335,190 |
| 2020 | 379 | 11,406 | 74 | 1.99 | $619,912 | $242,660 |
| 2019 | 333 | 5,622 | 73 | 1.91 | $471,295 | $180,542 |
| 2018 | 39 | 192 | 76 | 1.97 | $38,557 | $14,017 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 18 services
| Botox | 34 | $177,662 | None |
| Return visit (30+ min) | 330 | $163,314 | $102 |
| Muscle electrical test | 189 | $31,277 | $86 |
| Nerve test | 142 | $26,910 | $171 |
| New patient visit (45+ min) | 168 | $21,361 | $127 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 58 | $9,955 | $98 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 17 | $6,131 | $136 |
| Injection of trigger points, 3 or more muscles | 46 | $5,899 | $50 |
| Nerve test | 48 | $5,521 | $108 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 12 | $5,508 | $125 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 16 | $5,376 | $55 |
| Short return visit (20+ min) | 57 | $5,091 | $72 |
| Muscle electrical test | 21 | $4,484 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,418 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,179 | $98 |
| Ultrasonic guidance for needle placement | 13 | $768 | $45 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 15 | $116 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 46 | $66 | None |
2022: 24 services
| Botox | 32 | $149,646 | None |
| Return visit (30+ min) | 261 | $80,260 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 116 | $30,963 | $60 |
| Muscle electrical test | 156 | $27,089 | $92 |
| Nerve test | 115 | $24,070 | $191 |
| New patient visit (45+ min) | 153 | $20,630 | $135 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $14,252 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $12,571 | $86 |
| Short return visit (20+ min) | 66 | $7,497 | $69 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 39 | $7,424 | $98 |
| Hospital discharge day management, more than 30 minutes | 69 | $6,488 | $90 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 13 | $5,384 | $146 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 12 | $5,277 | $132 |
| Injection of trigger points, 3 or more muscles | 22 | $5,138 | $54 |
| Nerve test | 43 | $4,985 | $116 |
| Muscle electrical test | 18 | $3,967 | $75 |
| Initial nursing facility care with moderate level of medical decision making, per day at least 35 minutes | 28 | $3,265 | $109 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 17 | $2,396 | $58 |
| Ultrasonic guidance for needle placement | 16 | $896 | $53 |
| Hospital discharge day management, 30 minutes or less | 11 | $679 | $62 |
| Injection of trigger points, 1-2 muscles | 11 | $530 | $48 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 11 | $70 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 32 | $45 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 14 | $1 | None |
2021: 19 services
| Botox | 25 | $78,566 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 145 | $41,714 | $61 |
| Return visit (30+ min) | 172 | $41,092 | $111 |
| Short return visit (20+ min) | 111 | $22,427 | $79 |
| New patient visit (45+ min) | 159 | $22,079 | $139 |
| Muscle electrical test | 119 | $20,866 | $92 |
| Nerve test | 90 | $19,496 | $201 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 96 | $17,519 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 97 | $15,776 | $87 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 44 | $8,339 | $100 |
| Hospital discharge day management, more than 30 minutes | 87 | $8,251 | $91 |
| Injection of trigger points, 3 or more muscles | 38 | $7,729 | $55 |
| Nerve test | 31 | $4,386 | $129 |
| Muscle electrical test | 15 | $2,427 | $78 |
| Ultrasonic guidance for needle placement | 21 | $1,460 | $52 |
| Injection of trigger points, 1-2 muscles | 13 | $1,016 | $46 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 16 | $212 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 37 | $80 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 64 | $6 | None |
2020: 20 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 206 | $51,205 | $61 |
| Botox | 12 | $37,669 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 146 | $22,818 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 131 | $22,763 | $170 |
| Return visit (30+ min) | 92 | $15,948 | $91 |
| Short return visit (20+ min) | 88 | $13,482 | $65 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 140 | $11,504 | $33 |
| Hospital discharge day management, more than 30 minutes | 108 | $10,131 | $92 |
| New patient visit (45+ min) | 72 | $8,795 | $122 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 40 | $7,051 | $79 |
| Muscle electrical test | 60 | $5,885 | $88 |
| Nerve test | 23 | $4,780 | $208 |
| Injection of trigger points, 3 or more muscles | 19 | $3,938 | $55 |
| Nerve test | 28 | $3,832 | $132 |
| Injection of trigger points, 1-2 muscles | 25 | $1,893 | $44 |
| Muscle electrical test | 11 | $1,696 | $74 |
| Ultrasonic guidance for needle placement | 20 | $1,341 | $50 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,069 | $59 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 21 | $295 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 27 | $140 | None |
2019: 15 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 132 | $33,887 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 115 | $21,435 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 105 | $19,163 | $168 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 131 | $15,102 | $33 |
| Return visit (30+ min) | 61 | $10,521 | $92 |
| Muscle electrical test | 77 | $9,803 | $82 |
| Hospital discharge day management, more than 30 minutes | 90 | $8,505 | $90 |
| New patient visit (45+ min) | 60 | $8,221 | $137 |
| Short return visit (20+ min) | 40 | $4,307 | $64 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 27 | $4,173 | $93 |
| Nerve test | 21 | $3,632 | $173 |
| Nerve test | 27 | $3,563 | $132 |
| Nerve test | 15 | $3,018 | $201 |
| Initial nursing facility care with moderate level of medical decision making, per day at least 35 minutes | 15 | $1,644 | $110 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 25 | $349 | None |
2018: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $3,171 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,547 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $2,096 | $87 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,736 | $91 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $1,637 | $33 |
Medicaid work
$276,828 in 2024
Medicaid paid $276,828 for 2,675 billed services this clinician did in 2024, up to 273 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Botox | 138 | $118,788 |
| Return visit (30+ min) | 1,877 | $82,188 |
| Muscle electrical test | 176 | $25,285 |
| Nerve test | 76 | $17,569 |
| New patient visit (45+ min) | 159 | $12,716 |
| Nerve test | 53 | $7,695 |
| Injection(s); single or multiple trigger point(s), 3 or more muscles | 105 | $6,909 |
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 24 | $2,960 |
| DRAIN/INJ JOINT/BURSA W/US | 40 | $2,534 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 27 | $184 |
| 2024 | 2,675 | 10 | 273 | $276,828 |
| 2023 | 3,920 | 11 | 230 | $475,933 |
| 2022 | 2,122 | 9 | 204 | $184,077 |
| 2021 | 1,803 | 10 | 100 | $112,030 |
| 2020 | 135 | 4 | 17 | $9,080 |
See the largest Medicaid services in earlier years
2023
| Botox | 129 | $209,188 |
| Return visit (30+ min) | 2,724 | $120,375 |
| Muscle electrical test | 370 | $57,504 |
| Nerve test | 246 | $56,256 |
| New patient visit (45+ min) | 215 | $17,216 |
| Injection(s); single or multiple trigger point(s), 3 or more muscles | 83 | $5,545 |
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 42 | $5,198 |
| Short return visit (20+ min) | 40 | $1,808 |
| Nerve test | 12 | $1,733 |
| DRAIN/INJ JOINT/BURSA W/US | 17 | $831 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 42 | $279 |
2022
| Return visit (30+ min) | 1,270 | $56,048 |
| Muscle electrical test | 330 | $45,231 |
| Nerve test | 177 | $37,414 |
| Botox | 12 | $23,666 |
| New patient visit (45+ min) | 202 | $15,846 |
| Nerve test | 25 | $3,572 |
| Short return visit (20+ min) | 43 | $1,300 |
| DRAIN/INJ JOINT/BURSA W/US | 12 | $724 |
| Lidocaine injection | 51 | $275 |
2021
| Return visit (30+ min) | 766 | $41,432 |
| Muscle electrical test | 175 | $25,354 |
| New patient visit (45+ min) | 174 | $16,692 |
| Nerve test | 49 | $11,412 |
| Short return visit (20+ min) | 146 | $7,539 |
| DRAIN/INJ JOINT/BURSA W/US | 83 | $5,092 |
| Nerve test | 12 | $1,762 |
| Lidocaine injection | 268 | $1,136 |
| Injection(s); single or multiple trigger point(s), 3 or more muscles | 13 | $860 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 117 | $750 |
2020
| Muscle electrical test | 32 | $3,873 |
| New patient visit (45+ min) | 29 | $2,398 |
| Return visit (30+ min) | 47 | $2,074 |
| Short return visit (20+ min) | 27 | $735 |
Drugs they prescribed that Part D paid
$75,681
Pharmacies billed $75,681 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 20% of their Part D prescriptions (216 of 1,097) in 2024. Above the middle of the specialty; the typical physical medicine and rehabilitation clinician is at 12%. Long-acting opioids: 12% of their opioid prescriptions.
1,003 generic and 94 brand-name prescriptions · $75,681 in drug cost · 11 antibiotic prescriptions · 17 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 25 | $8,428 | $337 |
| Xarelto | 18 | $5,400 | $300 |
| Clonidine | 11 | $2,636 | $240 |
| Hydrocodone-Acetaminophen | 83 | $1,576 | $19 |
| Oxycodone-Acetaminophen | 53 | $1,429 | $27 |
See all 25 drugs
| Eliquis | 25 | $8,428 | $337 |
| Xarelto | 18 | $5,400 | $300 |
| Clonidine | 11 | $2,636 | $240 |
| Hydrocodone-Acetaminophen | 83 | $1,576 | $19 |
| Oxycodone-Acetaminophen | 53 | $1,429 | $27 |
| Gabapentin | 135 | $1,260 | $9 |
| Pregabalin | 47 | $549 | $12 |
| Lidocaine | 12 | $545 | $45 |
| Tizanidine | 55 | $519 | $9 |
| Oxycodone | 25 | $481 | $19 |
| Baclofen | 30 | $464 | $15 |
| Labetalol | 13 | $416 | $32 |
| Cyclobenzaprine | 47 | $381 | $8 |
| Famotidine | 24 | $357 | $15 |
| Nifedipine Er | 13 | $353 | $27 |
| Hydralazine | 12 | $326 | $27 |
| Atorvastatin | 27 | $296 | $11 |
| Methocarbamol | 34 | $191 | $6 |
| Pantoprazole | 26 | $186 | $7 |
| Allopurinol | 13 | $179 | $14 |
| Metoprolol | 11 | $167 | $15 |
| Lisinopril | 14 | $153 | $11 |
| Meloxicam | 40 | $102 | $3 |
| Ibuprofen | 14 | $77 | $5 |
| Tramadol | 19 | $38 | $2 |
Year by year
| 2024 | 1,097 | 201 | 20% (216) | 9% | $75,681 |
| 2023 | 1,304 | 192 | 12% (158) | 15% | $122,124 |
| 2022 | 861 | 206 | 14% (122) | None | $58,617 |
| 2021 | 741 | 167 | 11% (84) | None | $41,804 |
| 2020 | 670 | 137 | 4% (27) | None | $33,198 |
| 2019 | 366 | 100 | 6% (21) | 13% | $17,147 |
| 2018 | 197 | 43 | None | None | $7,887 |
| 2017 | 194 | 34 | None | 9% | $7,413 |
| 2016 | 127 | 20 | None | None | $6,473 |
| 2015 | 77 | None | None | 29% | $7,042 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 35 drugs
| Diclofenac | 52 | $13,378 | $257 |
| Eliquis | 41 | $10,553 | $257 |
| Xarelto | 34 | $7,532 | $222 |
| Levemir | 18 | $5,928 | $329 |
| Pregabalin | 55 | $4,272 | $78 |
| Hydrocodone-Acetaminophen | 83 | $2,824 | $34 |
| Jardiance | 11 | $2,026 | $184 |
| Gabapentin | 105 | $1,808 | $17 |
| Baclofen | 43 | $1,663 | $39 |
| Lidocaine | 24 | $1,187 | $49 |
| Tizanidine | 42 | $985 | $23 |
| Oxycodone-Acetaminophen | 23 | $572 | $25 |
| Nystatin | 22 | $513 | $23 |
| Duloxetine | 11 | $484 | $44 |
| Prednisolone Acetate | 12 | $444 | $37 |
| Metoprolol | 22 | $424 | $19 |
| Cyclobenzaprine | 31 | $397 | $13 |
| Methocarbamol | 18 | $347 | $19 |
| Amiodarone | 19 | $343 | $18 |
| Tamsulosin | 26 | $257 | $10 |
| Atorvastatin | 21 | $210 | $10 |
| Famotidine | 19 | $206 | $11 |
| Meloxicam | 34 | $200 | $6 |
| Ibuprofen | 15 | $191 | $13 |
| Pantoprazole | 20 | $154 | $8 |
| Oxycodone | 11 | $154 | $14 |
| Potassium Chloride | 15 | $138 | $9 |
| Metoprolol | 22 | $137 | $6 |
| Losartan | 14 | $124 | $9 |
| Prednisone | 14 | $111 | $8 |
| Furosemide | 15 | $92 | $6 |
| Naproxen | 12 | $88 | $7 |
| Acetaminophen-Codeine | 13 | $76 | $6 |
| Risperidone | 15 | $73 | $5 |
| Tramadol | 11 | $50 | $5 |
2022: 16 drugs
| Botox | 11 | $16,395 | $1,490 |
| Lidocaine | 29 | $4,360 | $150 |
| Pregabalin | 56 | $3,835 | $68 |
| Diclofenac | 62 | $3,216 | $52 |
| Hydrocodone-Acetaminophen | 68 | $1,879 | $28 |
| Gabapentin | 126 | $1,697 | $13 |
| Baclofen | 42 | $1,039 | $25 |
| Tizanidine | 62 | $559 | $9 |
| Oxycodone | 15 | $224 | $15 |
| Meloxicam | 40 | $178 | $4 |
| Tramadol | 21 | $157 | $7 |
| Cyclobenzaprine | 15 | $125 | $8 |
| Atorvastatin | 20 | $121 | $6 |
| Pantoprazole | 12 | $107 | $9 |
| Amlodipine Besylate | 13 | $79 | $6 |
| Lisinopril | 12 | $47 | $4 |
2021: 14 drugs
| Pregabalin | 29 | $2,681 | $92 |
| Gabapentin | 92 | $1,159 | $13 |
| Diclofenac | 26 | $939 | $36 |
| Baclofen | 25 | $905 | $36 |
| Tizanidine | 40 | $823 | $21 |
| Hydrocodone-Acetaminophen | 37 | $770 | $21 |
| Amitriptyline | 16 | $280 | $18 |
| Atorvastatin | 35 | $198 | $6 |
| Cyclobenzaprine | 13 | $163 | $13 |
| Pantoprazole | 19 | $150 | $8 |
| Meloxicam | 42 | $144 | $3 |
| Tramadol | 29 | $124 | $4 |
| Amlodipine Besylate | 17 | $81 | $5 |
| Lisinopril | 11 | $48 | $4 |
2020: 14 drugs
| Eliquis | 11 | $5,355 | $487 |
| Breo Ellipta | 12 | $4,445 | $370 |
| Diclofenac | 56 | $1,531 | $27 |
| Baclofen | 30 | $735 | $25 |
| Gabapentin | 70 | $637 | $9 |
| Cyclobenzaprine | 23 | $465 | $20 |
| Atorvastatin | 37 | $248 | $7 |
| Pantoprazole | 25 | $146 | $6 |
| Tamsulosin | 12 | $100 | $8 |
| Meloxicam | 24 | $98 | $4 |
| Lisinopril | 14 | $97 | $7 |
| Hydrocodone-Acetaminophen | 12 | $71 | $6 |
| Carvedilol | 13 | $66 | $5 |
| Amlodipine Besylate | 11 | $41 | $4 |
2019: 5 drugs
| Diclofenac | 35 | $1,210 | $35 |
| Gabapentin | 22 | $333 | $15 |
| Baclofen | 15 | $305 | $20 |
| Atorvastatin | 28 | $182 | $6 |
| Hydrocodone-Acetaminophen | 16 | $161 | $10 |
2018: 1 drug
| Atorvastatin | 19 | $150 | $8 |
2017: 4 drugs
| Tizanidine | 33 | $1,152 | $35 |
| Gabapentin | 25 | $394 | $16 |
| Amitriptyline | 29 | $236 | $8 |
| Meloxicam | 12 | $35 | $3 |
Money from drug and device companies
$3,837 in 2025
| 2025 | 9 | 83 | None | $3,837 |
| 2024 | 10 | 91 | None | $3,018 |
| 2023 | 14 | 103 | None | $4,575 |
| 2022 | 16 | 96 | None | $3,042 |
| 2021 | 11 | 74 | None | $1,726 |
| 2020 | 3 | 16 | None | $267 |
| 2019 | 10 | 28 | None | $2,812 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | General - Therapies | $2,291 | 28 payments
|
| Abbvie | Botox | $895 | 37 payments
|
| SPR Therapeutics | Sprint Pns System | $341 | 8 payments
|
| Medtronic | Inceptiv | $99 | 1 payment
|
| Vertex Pharmaceuticals | Journavx | $92 | 3 payments
|
| Galderma Laboratories L.P. | Dysport | $71 | 3 payments
|
See all 83 published payments
| Boston Scientific | Meals · 2025-12-17 | Intracept | $25 |
| Abbvie | Meals · 2025-12-17 | Ubrelvy | $24 |
| SPR Therapeutics | Meals · 2025-12-05 | Sprint Pns System | $34 |
| Boston Scientific | Meals · 2025-12-04 | General - Pain Management | $138 |
| Abbvie | Meals · 2025-12-04 | Qulipta | $9 |
| Vertex Pharmaceuticals | Meals · 2025-12-04 | Journavx | $36 |
| Abbvie | Meals · 2025-12-02 | Qulipta | $9 |
| Boston Scientific | Meals · 2025-11-26 | General - Pain Management | $27 |
| Abbvie | Meals · 2025-11-26 | Qulipta | $33 |
| Abbvie | Meals · 2025-11-25 | Botox | $6 |
| Abbvie | Meals · 2025-11-20 | Botox | $8 |
| Abbvie | Meals · 2025-11-20 | Botox | $9 |
| Abbvie | Meals · 2025-11-19 | Botox | $32 |
| Abbvie | Meals · 2025-11-19 | Botox | $140 |
| Boston Scientific | Meals · 2025-11-18 | Spectra Wavewriter | $160 |
| Boston Scientific | Meals · 2025-11-12 | Intracept | $105 |
| Boston Scientific | Meals · 2025-11-11 | Wavewriter Alpha Prime 16 | $46 |
| Boston Scientific | Meals · 2025-11-06 | Wavewriter Alpha Prime 16 | $10 |
| Mml US | Meals · 2025-11-04 | Reactiv8 | $14 |
| Abbvie | Meals · 2025-10-30 | Botox | $32 |
| SPR Therapeutics | Meals · 2025-10-29 | Sprint Pns System | $44 |
| Abbvie | Meals · 2025-10-29 | Botox | $14 |
| Pfizer | Meals · 2025-10-23 | Nurtec Odt | $18 |
| Abbvie | Meals · 2025-10-22 | Botox | $30 |
| Abbvie | Meals · 2025-10-21 | Qulipta | $19 |
| Boston Scientific | Meals · 2025-10-09 | General - Pain Management | $135 |
| Abbvie | Meals · 2025-09-30 | Qulipta | $33 |
| Boston Scientific | Meals · 2025-09-23 | Intracept | $36 |
| SPR Therapeutics | Meals · 2025-09-19 | Sprint Pns System | $43 |
| Abbvie | Meals · 2025-09-19 | Ubrelvy | $11 |
| Galderma Laboratories L.P. | Meals · 2025-09-18 | None | $22 |
| Vertex Pharmaceuticals | Meals · 2025-09-15 | Journavx | $31 |
| Boston Scientific | Meals · 2025-09-10 | General - Pain Management | $23 |
| Boston Scientific | Meals · 2025-09-05 | Wavewriter Alpha Prime 16 | $35 |
| Abbvie | Meals · 2025-08-21 | Qulipta | $28 |
| Abbvie | Meals · 2025-08-20 | Ubrelvy | $11 |
| Boston Scientific | Meals · 2025-08-13 | General - Pain Management | $21 |
| Boston Scientific | Meals · 2025-08-07 | General - Pain Management | $21 |
| Abbvie | Meals · 2025-07-29 | Botox | $19 |
| Abbvie | Meals · 2025-07-23 | Botox | $10 |
| Boston Scientific | Meals · 2025-07-22 | Intracept | $23 |
| Abbvie | Meals · 2025-07-16 | Qulipta | $17 |
| SPR Therapeutics | Meals · 2025-07-11 | Sprint Pns System | $45 |
| Abbvie | Meals · 2025-07-08 | Botox | $125 |
| Abbvie | Meals · 2025-06-24 | Ubrelvy | $21 |
| Galderma Laboratories L.P. | Meals · 2025-06-11 | Dysport | $30 |
| SPR Therapeutics | Meals · 2025-06-06 | Sprint Pns System | $38 |
| Boston Scientific | Meals · 2025-06-03 | Wavewriter Alpha Prime 16 | $29 |
| Boston Scientific | Meals · 2025-06-03 | Intracept | $24 |
| Merz North America | Meals · 2025-05-27 | None | $17 |
| Boston Scientific | Meals · 2025-05-24 | General - Pain Management | $35 |
| Boston Scientific | Meals · 2025-05-22 | Wavewriter Alpha Prime 16 | $39 |
| Abbvie | Meals · 2025-05-22 | Botox | $14 |
| Galderma Laboratories L.P. | Meals · 2025-05-21 | Dysport | $20 |
| Abbvie | Meals · 2025-05-15 | Botox | $33 |
| Abbvie | Meals · 2025-05-15 | Botox | $2 |
| Abbvie | Meals · 2025-05-15 | Botox | $9 |
| Boston Scientific | Meals · 2025-05-01 | General - Pain Management | $35 |
| Abbvie | Meals · 2025-05-01 | Botox | $15 |
| Medtronic | Meals · 2025-04-29 | Inceptiv | $99 |
| Abbvie | Meals · 2025-04-26 | Ubrelvy | $7 |
| Boston Scientific | Meals · 2025-04-22 | Wavewriter Alpha Prime 16 | $36 |
| Abbvie | Meals · 2025-04-21 | Qulipta | $30 |
| Abbvie | Meals · 2025-04-10 | Qulipta | $4 |
| SPR Therapeutics | Meals · 2025-04-07 | Sprint Pns System | $45 |
| Boston Scientific | Meals · 2025-03-23 | General - Pain Management | $11 |
| Abbvie | Meals · 2025-03-20 | Ubrelvy | $17 |
| Boston Scientific | Meals · 2025-03-15 | General - Therapies | $204 |
| Boston Scientific | Travel · 2025-03-15 | General - Therapies | $56 |
| Boston Scientific | Meals · 2025-03-14 | General - Pain Management | $148 |
| Boston Scientific | Travel · 2025-03-14 | General - Therapies | $363 |
| Boston Scientific | Travel · 2025-03-14 | General - Therapies | $316 |
| Vertex Pharmaceuticals | Meals · 2025-03-11 | Journavx | $25 |
| SPR Therapeutics | Meals · 2025-03-07 | Sprint Pns System | $43 |
| Abbvie | Meals · 2025-03-05 | Botox | $31 |
| Abbvie | Meals · 2025-02-27 | Qulipta | $20 |
| Abbvie | Meals · 2025-02-12 | Botox | $28 |
| SPR Therapeutics | Meals · 2025-02-07 | Sprint Pns System | $49 |
| Boston Scientific | Meals · 2025-01-30 | General - Pain Management | $143 |
| Abbvie | Meals · 2025-01-22 | Botox | $9 |
| Abbvie | Meals · 2025-01-16 | Qulipta | $9 |
| Abbvie | Meals · 2025-01-14 | Botox | $28 |
| Boston Scientific | Meals · 2025-01-07 | General - Pain Management | $49 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,018
| Boston Scientific | Na | $857 | 13 payments
|
| Abbvie | Botox | $778 | 42 payments
|
| Medtronic | Intellis Adaptivestim | $607 | 16 payments
|
| SPR Therapeutics | Sprint Pns System | $403 | 5 payments
|
| Pfizer | Nurtec Odt | $132 | 7 payments
|
| Galderma Laboratories L.P. | None | $79 | 2 payments
|
| Saluda Medical Americas | Evoke | $68 | 2 payments
|
| Painteq | Painteq | $50 | 2 payments
|
| Indivior | Sublocade | $29 | 1 payment
|
| Novo Nordisk | Wegovy | $16 | 1 payment
|
2023: $4,575
| Boston Scientific | Axios | $1,705 | 22 payments
|
| Medtronic | Intellis Adaptivestim | $779 | 18 payments
|
| AbbVie | Botox | $768 | 39 payments
|
| SPR Therapeutics | Sprint Pns System | $606 | 5 payments
|
| Painteq | Painteq | $190 | 5 payments
|
| Biotronik Nro | Biotronik | $136 | 1 payment
|
| Merz North America | Xeomin | $86 | 1 payment
|
| IBSA Pharma | Licart | $81 | 1 payment
|
| Pfizer | Paxlovid | $59 | 3 payments
|
| Novo Nordisk | Saxenda | $40 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $37 | 1 payment
|
| Relievant Medsystems | Intracept | $33 | 2 payments
|
| Galderma Laboratories L.P. | None | $32 | 2 payments
|
| Otsuka America Pharmaceutical | Rexulti | $23 | 1 payment
|
2022: $3,042
| Boston Scientific | General - Pain Management | $698 | 17 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $516 | 1 payment
|
| Allergan | Botox | $439 | 22 payments
|
| Medtronic | Intellis Adaptivestim | $321 | 10 payments
|
| Abbvie | Botox | $289 | 20 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $207 | 6 payments
|
| Nalu Medical | Nalu Neurostimulation System | $183 | 4 payments
|
| Abbott Laboratories | Proclaim | $93 | 3 payments
|
| DePuy Synthes Sales | Monovisc | $63 | 2 payments
|
| Galderma Laboratories L.P. | None | $50 | 3 payments
|
| Merz North America | None | $44 | 2 payments
|
| Horizon Therapeutics plc | Pennsaid | $35 | 2 payments
|
| Amgen | Aimovig | $31 | 1 payment
|
| Lilly USA | Emgality | $30 | 1 payment
|
| Painteq | Painteq | $24 | 1 payment
|
| Kowa Pharmaceuticals America | Seglentis | $20 | 1 payment
|
2021: $1,726
| Allergan | Botox | $514 | 49 payments
|
| Medtronic | Intellis | $456 | 4 payments
|
| Nevro | Omnia | $226 | 2 payments
|
| Galderma Laboratories L.P. | None | $155 | 5 payments
|
| Team_Makena_LLC | None | $146 | 1 payment
|
| Pacira Therapeutics | Zilretta | $83 | 3 payments
|
| Bioventus | Gelsyn-3 | $42 | 1 payment
|
| Horizon Therapeutics plc | Pennsaid | $35 | 2 payments
|
| GRT US Holding | Qutenza | $28 | 1 payment
|
| Arbor Pharmaceuticals | Horizant | $23 | 1 payment
|
| AbbVie | Qulipta | $18 | 1 payment
|
2020: $267
| Allergan | Botox | $177 | 12 payments
|
| Flexion Therapeutics | Zilretta | $52 | 2 payments
|
| Horizon Therapeutics plc | Pennsaid | $39 | 2 payments
|
2019: $2,812
| Arthrex | None | $1,948 | 4 payments
|
| Micromed | None | $197 | 1 payment
|
| Ipsen Biopharmaceuticals | Dysport | $181 | 4 payments
|
| Allergan | Botox Cosmetic | $157 | 3 payments
|
| DePuy Synthes Sales | Orthovisc | $132 | 2 payments
|
| Team_Makena_LLC | None | $103 | 10 payments
|
| Bioventus | Durolane | $40 | 1 payment
|
| Flexion Therapeutics | Zilretta | $22 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $19 | 1 payment
|
| Horizon Therapeutics plc | Pennsaid | $13 | 1 payment
|
Professional record
- NPI
- 1801273305
- Licence
- CA 20A16383
- Trained
- College of Osteo Med of the Pacific at Pomona, 2014 · 12 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 208100000X (208100000X)
- Mailing address
- 1280 S Victoria Avenue, Suite #250, Ventura, CA, 93003
- NPI first listed
- 2015-05-04
- NPI last updated
- 2022-12-16
- NPI record certified
- 2022-12-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1600 N Rose Ave, Oxnard, CA, 93030